OGI vs. RIGL, ZVRA, TRVI, DSGN, LFCR, GALT, PRLD, MACK, ALIM, and ATOS
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Rigel Pharmaceuticals (RIGL), Zevra Therapeutics (ZVRA), Trevi Therapeutics (TRVI), Design Therapeutics (DSGN), Lifecore Biomedical (LFCR), Galectin Therapeutics (GALT), Prelude Therapeutics (PRLD), Merrimack Pharmaceuticals (MACK), Alimera Sciences (ALIM), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
Rigel Pharmaceuticals has higher earnings, but lower revenue than Organigram. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Rigel Pharmaceuticals received 253 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 68.81% of users gave Rigel Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has a net margin of -21.47% compared to Rigel Pharmaceuticals' net margin of -173.48%. Organigram's return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Rigel Pharmaceuticals currently has a consensus target price of $5.81, suggesting a potential upside of 384.38%. Given Organigram's higher probable upside, research analysts clearly believe Rigel Pharmaceuticals is more favorable than Organigram.
Rigel Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Organigram. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 0 mentions for Organigram. Rigel Pharmaceuticals' average media sentiment score of 1.00 beat Organigram's score of -0.33 indicating that Organigram is being referred to more favorably in the news media.
Summary
Rigel Pharmaceuticals beats Organigram on 12 of the 18 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
